• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Renalytix Ai Plc ADR (NQ: RNLX )

    0.2071 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Oct 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Renalytix Ai Plc ADR

    < Previous 1 2 3 4 5 6 7 8 Next >
    Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
    From Renalytix plc
    Via GlobeNewswire
    Vail Resorts, NIO And 3 Stocks To Watch Heading Into Friday
    With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
    Via Benzinga
    Markets Turn Bullish After Dow Rises For Third Straight Session
    The CNN Money Fear and Greed index showed an improvement in overall sentiment among U.S. investors on Thursday. U.S. stocks closed higher on Thursday following the release of initial jobless claims... 
    Via Benzinga
    Earnings Preview For Renalytix
    Via Benzinga
    Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
    From Renalytix plc
    Via GlobeNewswire
    Renalytix AI Earnings Preview
    Via Benzinga
    Preview: Renalytix AI's Earnings
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time for a look at the biggest pre-market stock movers on Tuesday morning with all the details traders need to know about! 
    Via InvestorPlace
    Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
    Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage 
    From Renalytix plc
    Via GlobeNewswire
    New Published Real-World Evidence Shows KidneyIntelX™ Utility
    From Renalytix plc
    Via GlobeNewswire
    Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
    From Renalytix plc
    Via GlobeNewswire
    Earnings Scheduled For March 30, 2023
    Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
    Via Benzinga
    Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
    From Renalytix plc
    Via GlobeNewswire
    Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
    From Renalytix plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
    From Renalytix plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
    Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. 
    Via Benzinga
    Renalytix announces a c.$20.3 million private placement
    From Renalytix plc
    Via GlobeNewswire
    Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
    Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease 
    From Renalytix plc
    Via GlobeNewswire
    Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
    Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease 
    From Renalytix AI, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
    First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patients 
    From Renalytix AI, Inc.
    Via GlobeNewswire
    Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
    From Renalytix AI, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 30, 2022
    Companies Reporting Before The Bell • Seadrill (NYSE:SDRL) is expected to report earnings for its third quarter. • Build-A-Bear Workshop (NYSE:BBW) is likely to report earnings for its third quarter. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
    From Renalytix AI, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.